Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010111
Filing Date
2025-05-14
Accepted
2025-05-14 09:00:40
Documents
56
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 838247
2 EX-31.1 ex31-1.htm EX-31.1 21910
3 EX-31.2 ex31-2.htm EX-31.2 22091
4 EX-32.1 ex32-1.htm EX-32.1 11715
  Complete submission text file 0001641172-25-010111.txt   4585300

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE drma-20250331.xsd EX-101.SCH 32560
6 XBRL CALCULATION FILE drma-20250331_cal.xml EX-101.CAL 31855
7 XBRL DEFINITION FILE drma-20250331_def.xml EX-101.DEF 154112
8 XBRL LABEL FILE drma-20250331_lab.xml EX-101.LAB 295911
9 XBRL PRESENTATION FILE drma-20250331_pre.xml EX-101.PRE 236585
58 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 705084
Mailing Address 3525 DEL MAR HEIGHTS RD., #322 SAN DIEGO CA 92130
Business Address 3525 DEL MAR HEIGHTS RD., #322 SAN DIEGO CA 92130 (858)-223-0882
Dermata Therapeutics, Inc. (Filer) CIK: 0001853816 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40739 | Film No.: 25942975
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)